GSK updates share capital: 4.32B issued, 254.77M in treasury

Rhea-AI Filing Summary

GSK plc reported its monthly total voting rights and capital. As at 31 October 2025, the company had 4,315,423,599 Ordinary Shares of 31 ¼ pence each in issue, of which 254,768,344 were held in treasury. The resulting total number of voting rights is 4,060,655,255.

Shareholders may use this voting rights figure as the denominator when assessing whether they must notify holdings or changes under the FCA’s Disclosure Guidance and Transparency Rules.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 11/03/2025 - 01:37 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc

Total Voting Rights and Capital

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the 'Company') hereby notifies the market of the following:

The Company's issued share capital as at 31 October 2025 consisted of 4,315,423,599 shares of 31 ¼ pence each ('Ordinary Shares'), of which 254,768,344 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 4,060,655,255. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Notifications may be sent to company.secretary@gsk.com.

V A Whyte

Company Secretary

3 November 2025

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: November 03, 2025

By:/s/ VICTORIA WHYTE--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What total voting rights did GSK (GSK) report?

GSK reported 4,060,655,255 total voting rights as at 31 October 2025.

How many GSK shares were in issue and how many were held in treasury?

Issued share capital was 4,315,423,599 Ordinary Shares, with 254,768,344 held in treasury as at 31 October 2025.

What is the nominal value of GSK’s Ordinary Shares?

Each Ordinary Share has a nominal value of 31 ¼ pence.

How should GSK shareholders use the voting rights figure?

Shareholders may use 4,060,655,255 as the denominator to determine notification thresholds under the FCA’s DTR rules.

What date does GSK’s voting rights information relate to?

The figures are stated as at 31 October 2025.

Who signed the announcement for GSK?

It was signed by Victoria Whyte, Authorised Signatory for and on behalf of GSK plc.